02.09.16
A clinical study recently published in Aging Male, examined Testofen, Gencor’s proprietary herbal ingredient, adding to earlier research that has shown it to support healthy sexual desire and vitality, muscle mass, and free testosterone levels in men.
The study was a double-blind, randomized, placebo-controlled trial involving 120 healthy men aged between 43 and 70 years old and was conducted in Brisbane, Australia, over a period of 12 weeks. The trial examined the effect of Testofen, a specialized fenugreek seed extract, on the symptoms of possible androgen deficiency, sexual function and serum androgen concentrations in healthy aging males.
The primary outcome measure was efficacy of treatment for symptoms using the Aging Male Symptom questionnaire (AMS), which consists of 17 questions in 3 sub-scales, psychological, somatic and sexual. Secondary outcome measures were sexual function, assessed using the Derogatis Interview for Sexual Functioning-Self Report (DISF-SR) questionnaire, and serum sex hormone concentrations.
The results showed there was a significant decrease in AMS score over time and between the active and placebo groups, indicating a greater reduction in symptom severity in the active group compared with the placebo. Sexual function significantly improved in the active group, including the number of morning erections and the frequency of sexual activity. Both total serum testosterone and free testosterone increased in the active compared to placebo after 12 weeks of active treatment.
The study showed Testofen was safe and effective, reducing symptoms of possible androgen deficiency, improving sexual function, and increasing serum testosterone in healthy middle-aged and older men.
For more information: www.gencorpacific.com
The study was a double-blind, randomized, placebo-controlled trial involving 120 healthy men aged between 43 and 70 years old and was conducted in Brisbane, Australia, over a period of 12 weeks. The trial examined the effect of Testofen, a specialized fenugreek seed extract, on the symptoms of possible androgen deficiency, sexual function and serum androgen concentrations in healthy aging males.
The primary outcome measure was efficacy of treatment for symptoms using the Aging Male Symptom questionnaire (AMS), which consists of 17 questions in 3 sub-scales, psychological, somatic and sexual. Secondary outcome measures were sexual function, assessed using the Derogatis Interview for Sexual Functioning-Self Report (DISF-SR) questionnaire, and serum sex hormone concentrations.
The results showed there was a significant decrease in AMS score over time and between the active and placebo groups, indicating a greater reduction in symptom severity in the active group compared with the placebo. Sexual function significantly improved in the active group, including the number of morning erections and the frequency of sexual activity. Both total serum testosterone and free testosterone increased in the active compared to placebo after 12 weeks of active treatment.
The study showed Testofen was safe and effective, reducing symptoms of possible androgen deficiency, improving sexual function, and increasing serum testosterone in healthy middle-aged and older men.
For more information: www.gencorpacific.com